Codex_V5

Mutant	Antiviral	EC50 ratio	Phenotype	Assay	Reference
T37A			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
L38M			Natural polymorphism	Details	Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
L89P			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
D94N			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
K95E			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
H216R			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
G239C			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
Q244H			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
Q249H			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
K253Q			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
K253T			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
E254A			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
R258P			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
A283P			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
N294D			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
N320H	Letermovir	1.80	No resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
N329S	Letermovir	2.00	Low level resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
D344E	Letermovir	1.80	No resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
D344E	Maribavir	0.09	Possible hypersensitivity, no resistance	Details	Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
S345A			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
T350M	Letermovir	2.80	Low level resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
M359I	Letermovir	1.50	No resistance	Details	Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
T448I			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
C511F			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
I531V			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
L548V			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
L562F			Natural polymorphism	Details	Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
G635S			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
A659V			Natural polymorphism	Details	Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
A663V			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
D665E			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
A668P			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
F671S			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
R672K			Natural polymorphism	Details	New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
V673I			Natural polymorphism	Details	Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)